摘要
目的:分析淋巴瘤和多发性骨髓瘤患者自体外周血造血干细胞动员的影响因素,为优化自体造血干细胞动员方案提供参考。方法:收集2015年1月至2018年12月本中心收治的33例多发性骨髓瘤及淋巴瘤行自体造血干细胞动员患者的临床资料,分析性别、年龄、动员前化疗疗程、重组人粒细胞集落刺激因子用量、疾病类型及化疗方案与动员失败率的相关性。结果:疾病类型和动员前化疗疗程可影响造血干细胞动员的失败率(P<0.05);淋巴瘤患者动员失败率为42.1%,显著高于多发性骨髓瘤患者(7.1%)(P=0.026);采集前化疗疗程≥5个组失败率显著增高(P=0.016)。年龄、性别、重组人粒细胞集落刺激因子用量及化疗方案与干细胞动员失败率无显著相关性(P>0.05)。结论:采集前多疗程化疗及淋巴瘤患者是自体造血干细胞动员的不良因素。
Objective: To analyze the factors influencing the mobilization of autologous peripheral blood stem cells(auto-PBSCs) in patients with lymphoma and multiple myeloma, and provide reference for optimizing the autologous stem cell mobilization regimen. Methods: Clinical data of 33 multiple myeloma and lymphoma patients received autoPBSCs mobilization in our center from January 2015 to December 2018 were collected, the correlation of mobilization failure rate with gender, age, courses of chemotherapy before mobilization, does of recombinant human granulocyte colony stimulating factor(rhG-CSF), type of disease, and chemotherapy regimen were retrospectively analyzed. Results:Type of disease and course of pre-mobilization chemotherapy could affect the mobilization failure rate(P<0.05).The mobilization failure rate of lymphoma patients was 42.1%, which was significantly higher than 7.1% of multiple myeloma patients(P=0.026). The mobilization failure rate was higher in the group with chemotherapy courses≥ 5 before mobilization(P=0.016). Age, gender, dose of rhG-CSF, and chemotherapy regimen had no significant correlation with mobilization failure rate(P>0.05). Conclusion: Multi-course chemotherapy before collection and lymphoma patients are poor factors negatively impacting on auto-PBSCs mobilization.
作者
苏永锋
王艺志
宁红梅
胡亮钉
SU Yong-Feng;WANG Yi-Zhi;NING Hong-Mei;HU Liang-Ding(Department of Hematopoietic Stem Cell Transplantation,The Fifth Medical Center of PLA General Hospital,Beijing 100071,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2021年第6期1945-1949,共5页
Journal of Experimental Hematology
关键词
自体外周血造血干细胞动员
淋巴瘤
多发性骨髓瘤
化疗
autologous peripheral blood stem cells mobilization
lymphoma
multiple myeloma
chemotherapy